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Accepted 4 February 2013Kamani et al. [1] recently reported on the results of the
cord blood recipient cohort of the Sickle Cell Unrelated
Donor Transplant Trial (SCURT trial) of the Blood and
Marrow Transplant Clinical Trials Network. Of the 8 children
undergoing unrelated donor cord blood transplantation
(UCBT) after reduced-intensity conditioning with alemtu-
zumab, ﬂudarabine and melphalan, 5 had primary graft
failure resulting in a 1-year event-free survival of 37.5%. We
previously reported the outcome of reduced toxicity
conditioning (RTC) and UCBT in pediatric recipients [2,3].
We report here a similar experience with that of Kamani
et al. with an RTC regimen of busulfan, ﬂudarabine, and
alemtuzumab before UCBT in children with sickle cell
disease (SCD).
During the period of 2004 to 2010, we investigated the
combination of busulfan (3.2 to 4 mg/kg/day IV divided BID,
days -8 to -5), ﬂudarabine (30 mg/m2/day IV, days -8 to -3),
and alemtuzumab (2 mg/m2 day -6, 6 mg/m2 days -5,-4, and
20 mg/m2 days -3, -2; 54 mg/m2 total dose, days -6 to -2) as
we have previously described [4] as a conditioning regimen
for 8 consecutive pediatric patients with high-risk SCD
undergoing UCBT. Acute graft-versus-host disease (GVHD)
prophylaxis consisted of mycophenolate mofetil and tacro-
limus, as we have previously reported [5]. Median age of
patients was 3.6 years (range, 1 to 10 years) with a male-to-
female ratio of 7:1.
Among evaluable (5 of 8) UCBT recipients, 62.5% engraf-
ted neutrophils at median day 34 (range, 27 to 47). In addi-
tion to the 3 unrelated UCBT recipients who did not engraft
neutrophils, one unrelated UCBT recipient achieved absoluteFinancial disclosure: See Acknowledgments on page 677.
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>50% donor chimerism in whole blood by day þ60 and was
therefore classiﬁed as having primary graft failure. Of
evaluable UCBT recipients, 50% engrafted donor platelets at
median day 54 (range, 43 to 70).
The probability of grade II to grade IV acute GVHD was
50.0%, and the probability of grade III to grade IV acute GVHD
was 25.0%. One recipient developed chronic GVHD, which
was limited. Two-year event-free survival and overall
survival were 50% and 62.5%, respectively.
Three patients with primary graft failure died from
infection: one died from cytomegalovirus pneumonitis on
day þ84, another died of adenovirus on day þ128 and one
patient, who had developed primary graft failure due to
cytomegalovirus, received a second allograft 1 year later for
persistent aplasia and died of Candida parapsilosis.
Our institution’s experiences closely parallel the results
reported by Kamani et al. with high incidence of graft
failure after RTC and UCBT in pediatric recipients with
high-risk SCD. All 3 primary graft failures were associated
with viral infections. However, we previously reported no
change in incidence of systemic viral and invasive fungal
infections after RTC versus myeloablative conditioning
before allogeneic stem cell transplantation in pediatric
recipients [6].
Perhaps more immunosuppressive regimens in patients
with SCD undergoing UCBT may be necessary to overcome
immunologic barriers to engraftment in these patients.
Additionally, double cord blood transplantation, facilitative
cellular therapy, and ex vivo umbilical cord blood expan-
sion have the potential to improve outcomes in UCBT
recipients with SCD [7,8]. Alternate stem cell sources
should also be considered, such as matched unrelated
(currently being studied in the SCURT trial) or hap-
loidentical donors [9]. We are pursuing a new pilot study
to evaluate the efﬁcacy of T cell depleted haploidentical
allogeneic stem cell transplantation in patients with high
risk SCD lacking human leukocyte antigen matched-sibling
and 8/8 human leukocyte antigen-matched unrelated
donors [9,10].Transplantation.
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